The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Changes in liver function in patients with unresectable hepatocellular carcinoma (u-HCC), following extended periods from the initiation of atezolizumab plus bevacizumab (Atez/Bev), have not been fully investigated. METHODS: Of 148 u-HCC patients treated with first-line Atez/Bev, the study enrolled 38 u-HCC patients treated with first-line Atez/Bev, whose treatment response was initially evaluated as non-progressive disease (non-PD) and later as PD on imaging, and who then received second-line systemic chemotherapy. We evaluated the relationship between the period from the initiation of first-line Atez/Bev to that of second-line systemic chemotherapy with liver function and prognosis. RESULTS: According to the periods from the initiation of Atez/Bev to that of the second-line therapy, patients were classified into a long continuation group (Group-L, n = 19), ≥11 months; or a short continuation group (Group-S, n = 19), <11 months. The albumin-bilirubin (ALBI) score at the initiation of the second-line therapy did not differ significantly between the groups (median: -2.38 vs. -2.02, p = 0.559), and the change in ALBI score also did not differ significantly between the groups (median: 0.42 vs. 0.51, p = 0.770). Group-L had significantly better overall survival (OS) than Group-S (not reached vs. 18 months, p = 0.008). CONCLUSIONS: Liver function did not decrease even after long-term treatment with first-line Atez/Bev in patients who were able to progress to second-line therapy, indicating that long continuation of first-line Atez/Bev may be valuable for improving OS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study
- Date Crossref
- 28/03/2025
- Éditeur
- S. Karger AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nagoya City University Department of Gastroenterology and Metabolism pays non établi dans la noticeUniversité ou école supérieure
-
Toyokawa City Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Nagoya Daini Hospital pays non établi dans la noticeÉtablissement de santé
-
Gifu Prefectural Tajimi Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Kasugai Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Chukyo Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagoya Medical Center pays non établi dans la noticeÉtablissement de santé
-
Nagasaki Rousai Hospital pays non établi dans la noticeÉtablissement de santé
-
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Nagoya City East Medical Center Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Asahi Rousai Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
Department of Gastroenterology and Metabolism — Nagoya City University, Department of Gastroenterology — Toyokawa City Hospital et Japanese Red Cross Nagoya Daini Hospital, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.